Brief: Asit Biotech Launches Confirmatory Phase III Clinical Study With Gp-Asit+™ In Grass Pollen Rhinitis Prevention

European Medical Solutions SA

19/11/2018 06:02

Nov 19 (Reuters) - ASIT BIOTECH SA  ASIT.BR :
    * ASIT BIOTECH LAUNCHES ITS CONFIRMATORY PHASE III CLINICAL
STUDY
WITH GP-ASIT+™ IN GRASS POLLEN RHINITIS PREVENTION FOLLOWING THE
INVESTIGATOR MEETING HOSTED IN PRAGUE (CZECH REPUBLIC) ON
NOVEMBER 16-17, 2018
    * INVESTIGATORS FROM 82 PARTICIPATING CENTERS HAVE BEEN
TRAINED
AND PATIENT ENROLLMENT IS EXPECTED TO START AS EARLY AS JANUARY
2019
    * CLINICAL TRIAL AUTHORIZATIONS RECEIVED IN ALL 6
PARTICIPATING
COUNTRIES
    * STUDY RESULTS EXPECTED IN DECEMBER 2019
    * BASED ON LEARNINGS FROM FIRST PHASE III STUDY, MAJOR
IMPROVEMENTS HAVE BEEN SUCCESSFULLY IMPLEMENTED TO MAXIMIZE
PROBABILITY OF SUCCESS
    * FIRST CLINICAL TRIAL AUTHORIZATION SUBMISSION FOR
PNT-ASIT+™ IN
PEANUT ALLERGY EXPECTED BY END OF H1 2019

Source text for Eikon:  ID:nBw6cVFQSa 
Further company coverage:  ASIT.BR 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))